Live Biotherapeutics Drug Discovery Service for Amyotrophic Lateral Sclerosis (ALS)
Creative Biolabs, headquartered in New York City, is a world-renowned provider of contract research services. We focus on next-generation probiotics research. We provide services and products to customers from around the world, from academic laboratories and small biotechnology start-ups to global biopharmaceutical companies. When you want to entrust a partner with complete project management, you can benefit from our expertise.
Overview
Amyotrophic lateral sclerosis (ALS), characterized by the loss of motor neurons in the spinal cord and brain, is a relatively rare and currently incurable neurodegenerative disease. Common neuropathological features of ALS include loss of motor neurons and axons, neuroinflammation, and aggregation of cytoplasmic proteins in the motor cortex and spinal cord. A growing number of studies have shown that there is an association between intestinal microbiota and a variety of nervous system diseases. Two of the most established physiologic functions of the human gut microbiome are metabolism and modulation of adaptive immunity. Host microbiome interactions can influence neurological conditions. The gut microbiota releases specific products into the gut, including short-chain fatty acids (SCFAs), secondary bile acids, and tryptophan metabolites. They interact with the CNS in two different ways: by spreading signals bottom-up, starting at a local level, or by crossing the gut barrier into the systemic circulation, or even acting on the CNS after crossing the blood-brain barrier. Accumulating evidence suggests that A. muciniphila plays an important role in brain function through the gut-brain axis and may serve as a therapeutic target for various neuropsychiatric disorders.
Gut Microbiota and ALS
The gut-brain axis is a two-way communication pathway connecting the central nervous system, gastrointestinal tract, and gut microbiota. It is mediated by products produced by bacteria and acts at the systemic level and through endocrine and neural mechanisms. Recent studies suggest that gut dysbiosis and altered gut bacterial composition contribute role in ALS etiology and progression of ALS.
-
Anti-inflammatory SCFAs produced by gut microbiota are potential therapeutic agents that affect ALS progression. One hypothesis is that gut bacteria may represent an epigenetic entity that interacts with environmental factors to determine pathogenic effects on the CNS.
-
The microbiota may affect CNS and neuronal health either directly through the production of neuroactive metabolites and toxins or indirectly through the regulation of immune responses, dietary compounds, or drug metabolism.
Fig.1 Relationship between microbiota and molecular changes in ALS patients.1
Next-generation Probiotic Strains at Creative Biolabs
Creative Biolabs can offer a range of next-generation probiotics for live biotherapeutics research, including but not limited to the following, click on Probiotic Strains to check out more strains you might be interested in.
Our Services for the Following Type/Similar ALS Research
|
Research Article
|
Available Services
|
|
Neuroprotective effect of a multistrain probiotic mixture in SOD1G93A mice by reducing SOD1 aggregation and targeting the microbiota-gut-brain axis.2
|
|
Creative Biolabs is a professional services company with a professional technical team working in live biotherapeutics. If you are interested in our services, please contact us for further communication.
References
-
Casani-Cubel, Julia, et al. "The impact of microbiota on the pathogenesis of amyotrophic lateral sclerosis and the possible benefits of polyphenols. An overview." Metabolites 11.2 (2021): 120.
-
Xin, Zikai, et al. "Neuroprotective effect of a multistrain probiotic mixture in SOD1G93A mice by reducing SOD1 aggregation and targeting the microbiota-gut-brain axis." (2023).
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
